Reneo Announces Pricing of Public Offering of Common Stock
RPHMDelisted Stock | USD 18.20 1.40 8.33% |
About 55% of Reneo Pharmaceuticals' investors are presently thinking to get in. The analysis of current outlook of investing in Reneo Pharmaceuticals suggests that some traders are interested regarding Reneo Pharmaceuticals' prospects. Reneo Pharmaceuticals' investing sentiment overview a quick insight into current market opportunities from investing in Reneo Pharmaceuticals. Many technical investors use Reneo Pharmaceuticals stock news signals to limit their universe of possible portfolio assets and to time the market correctly.
Reneo |
IRVINE, Calif., May 03, 2023 -- Reneo Pharmaceuticals, Inc. , a clinical-stage pharmaceutical company focused on the development and commercialization of therapies for patients
Read at benzinga.com
Reneo Pharmaceuticals Fundamental Analysis
We analyze Reneo Pharmaceuticals' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Reneo Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Reneo Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Earnings Per Share
Earnings Per Share Comparative Analysis
Reneo Pharmaceuticals is currently under evaluation in earnings per share category among its peers. Earnings per Share (EPS) denotes the portion of a company's earnings that is allocated to each share of common stock. To calculate Earnings per Share investors will need to take a company's net income, subtract any dividends for preferred stock, and divide it by the number of average outstanding shares. EPS is usually presented in two different ways: basic and diluted. Fully diluted Earnings per Share takes into account effects of warrants, options, and convertible securities and is generally viewed by analysts as a more accurate measure.
Reneo Pharmaceuticals Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Reneo Pharmaceuticals stock to make a market-neutral strategy. Peer analysis of Reneo Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Reneo Pharmaceuticals by comparing valuation metrics with similar companies.
Peers
Reneo Pharmaceuticals Related Equities
CNSP | Cns Pharmaceuticals | 10.00 | ||||
IMMX | Immix Biopharma | 6.67 | ||||
PRME | Prime Medicine, | 6.52 | ||||
CELC | Celcuity LLC | 5.81 | ||||
HOWL | Werewolf Therapeutics | 3.25 | ||||
KRON | Kronos Bio | 2.17 | ||||
HEPA | Hepion Pharmaceuticals | 2.04 | ||||
OCEA | Ocean Biomedical | 1.79 | ||||
RPRX | Royalty Pharma | 1.23 | ||||
VIR | Vir Biotechnology | 0.95 | ||||
NKTX | Nkarta | 0.41 | ||||
APLS | Apellis Pharmaceuticals | 0.85 | ||||
LEGN | Legend Biotech | 0.88 | ||||
ADPT | Adaptive Biotechnologies | 2.33 | ||||
KZR | Kezar Life | 2.92 | ||||
EWTX | Edgewise Therapeutics | 3.10 | ||||
CCCC | C4 Therapeutics | 5.25 | ||||
DNA | Ginkgo Bioworks | 5.48 | ||||
SMMT | Summit Therapeutics | 5.55 | ||||
CGEM | Cullinan Oncology | 6.82 |
Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in rate. You can also try the Portfolio Center module to all portfolio management and optimization tools to improve performance of your portfolios.
Other Consideration for investing in Reneo Stock
If you are still planning to invest in Reneo Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Reneo Pharmaceuticals' history and understand the potential risks before investing.
Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
Global Correlations Find global opportunities by holding instruments from different markets | |
Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
Bonds Directory Find actively traded corporate debentures issued by US companies | |
Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |
Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital |